4D-Path_logo_web_full-color.jpg
4D Path, University of Leeds Extend Contract to Collaboratively Validate New Technology to Help Doctors More Accurately Diagnose Breast Cancer
March 16, 2021 10:00 ET | 4D Path
NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the...
4D-Path_logo_web_full-color.jpg
Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path
December 15, 2020 10:00 ET | 4D Path
NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter,...
4D-Path_logo_web_full-color.jpg
4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images
November 12, 2020 10:00 ET | 4D Path
NEWTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- 4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT,...
FBI LOGO TM.png
[2020-2026] Precision Diagnostics Market Size, Share, Growth, Trends, Revenue, Value, Competitive Landscape, Forecast Report by Fortune Business Insights
September 30, 2020 08:57 ET | Fortune Business Insights
Pune, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Developments in The Human Genome Project have given tailwinds to the growth witnessed in the global precision diagnostics market. Fortune Business Insights...
IVS_logo_20160331_CMYK.jpg
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
November 29, 2018 06:00 ET | Invivoscribe, Inc.
SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
IVS_logo_20160331_CMYK.jpg
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib
November 27, 2018 06:00 ET | Invivoscribe, Inc.
SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to...
IVS_logo_20160331_CMYK.jpg
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
November 19, 2018 08:00 ET | Invivoscribe, Inc.
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...